Company research / SABS

SAB Biotherapeutics, Inc. (SABS)

Also trades as SABSW. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

CIK 0001833214 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Partial revenue. In this company's filings, reported revenue for the year ended 2025-12-31 is zero or negative beside a profit. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Key ratios (year ended 2025-12-31)

8.8%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-18

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Stock splits: 1-for-10, first reflected in a filing dated 2024-03-29. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView